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Abstract
Introduction: Diagnosis and monitoring of diabetes mellitus in sub-Saharan Africa, based on blood analyses, are hampered by infrastructural and 
cultural reasons. The first aim of this study was to evaluate the diagnostic accuracy of glycated nail proteins for diabetes mellitus. The second aim 
was to compare the course of short- and long-term glycemic biomarkers after 6 months of antidiabetic treatment. These objectives should support 
our hypothesis that glycated nail proteins could be used as an alternative glycemic biomarker.
Materials and methods: This case-control study consisted of 163 black diabetics and 67 non-diabetics of the South Kivu (Democratic Republic of 
Congo). Diagnostic accuracy of glycated nail proteins was evaluated using ROC curve analysis. At the start of the study, glycated nail protein con-
centrations were compared between diabetics and non-diabetics, using a nitro blue tetrazolium (NBT) colorimetric method. In a subgroup of 30 
diabetics, concentrations of glycated nail proteins, fasting glucose (Accu-Chek® Aviva), serum fructosamine (NBT) and HbA1c (DCA-2000+®) were 
measured at start and after 6 months. 
Results: ROC analysis yielded an AUC of 0.71 (95% confidence interval (CI): 0.65-0.76) and a cut-off point of 3.83 μmol/g nail. Concentration of 
glycated nail proteins was significantly higher (P < 0.001) in diabetics in comparison with non-diabetics. After 6 months of antidiabetic treatment, 
a significant drop in the fasting glucose concentration (P = 0.017) and concentration of glycated nail proteins (P = 0.008) was observed in contrast 
to serum fructosamine and HbA1c. 
Conclusions: Measurement of glycated nail proteins could be used to diagnose and monitor diabetes mellitus in sub-Saharan Africa. 
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Besides the high rates of communicable diseases, 
an increasing prevalence of diabetes mellitus is ob-
served in sub-Saharan Africa (1). In comparison 
with the current 19.8 million diabetics in this re-
gion, this number is expected to double by 2035 
(2). Screening and monitoring of diabetes mellitus 
is of utmost importance as it is associated with an 
important morbidity (heart disease, nephropathy, 
neuropathy, and retinopathy) and mortality, as 
well as with a negative influence on the local econ-
omies. In 2013, approximately 75% of all adult 
deaths due to diabetes mellitus in less-developed 
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regions, like sub-Saharan Africa, were in people 
under 60 years old (3).
Although hyperglycemia remains the biochemical 
hallmark of diabetes mellitus, several other glyce-
mic markers (fructosamine, glycated albumin, 
hemoglobin A1c (HbA1c), 1,5-anhydroglucitol) 
have been proposed for the diagnosis and follow 
up of this disease, each with their own advantages 
and limitations (4). Although HbA1c is the best sur-
rogate of the average blood glucose control in dia-
betics, this measurement is unavailable in most 
parts of Africa. Taking into consideration the lack 
of infrastructure and the aversion to blood sam-
pling in some populations of rural Africa, the 
measurement of glycated proteins (fructosamine) 
in human finger nails could be excellently suited 
for low-income countries. Fructosamine (1-amino-
1-deoxy-D-fructose) is the result of a non-enzy-
matic reaction of the carbonyl group of glucose 
with an amino group of circulating serum proteins. 
As the protein content of human nails is about 
80%, the physiological fructosamine/protein ratio 
is in the order of 2-2.5 µmol/g nail protein. In hu-
man nail clippings, a pure protein matrix in ab-
sence of interfering substances is found, which is 
ideal for fructasmine testing. 
The first aim of the study was to evaluate the diag-
nostic accuracy of measuring the concentration of 
glycated nail proteins for diabetes mellitus in a sub-
Saharan African population. The second aim of the 
study was to compare the course of short-term 
(fasting glucose concentration and serum fruc-
tosamine concentration) and long-term (concen-
tration of glycated nail proteins and HbA1c level) 
glycemic biomarkers after 6 months of antidiabet-
ic treatment. This study should make it possible to 
evaluate the hypothesis if glycated nail proteins 
could be utilized for the diagnosis and monitoring 
of diabetes mellitus in sub-Saharan Africa.
Materials and methods
Subjects
This case-control study was performed between 1 
June 2013 and 1 June 2014 in Bukavu, a city in the 
Democratic Republic of Congo (South Kivu prov-
ince). African patients with diabetes mellitus (novel 
diagnosis or under antidiabetic treatment) and 
with an HbA1c of ≥ 48 mmol/mol (6.5%)), consult-
ing the department of Internal Medicine of the 
Reference Provincial General Hospital of Bukavu, 
were included in the study. Diabetics already un-
der treatment and with an HbA1c of < 48 mmol/
mol (6.5%) were excluded from the study. Accord-
ing to the current World Health Organization 
(WHO) diagnostic criteria, an HbA1c value of 48 
mmol/mol (6.5%) was used to identify new pa-
tients with diabetes mellitus (5). The control group 
consisted of 67 healthy, non-diabetic African stu-
dents of the Faculty of Medicine of the Catholic 
University of Bukavu, who underwent a general 
clinical examination and a blood analysis, and did 
not take any medication. After signing the in-
formed consent, 230 subjects were involved in the 
study: 163 diabetics (87 females, 76 males, median 
age: 59 years, range: 13-87 years) and a control 
group (26 females, 41 males, median age: 22 
years, range: 20-77 years). The concentration of 
glycated nail proteins was compared between 
both groups. In a subgroup of 30 diabetic pa-
tients (14 females, 16 males, median age: 57 years, 
range: 14-87 years), the concentration of two 
short-term (fasting glucose concentration and 
fructosamine) and two long-term (glycated nail 
proteins and HbA1c) glycemic biomarkers was 
measured at start and after 6 months of antidia-
betic treatment. The procedures were performed 
in accordance with the ethical standards set by the 
responsible human ethics committee (Ghent Uni-
versity hospital BUN: B670201215602) and the 1975 
Helsinki Declaration.
Methods
Fasting blood samples were collected in the morn-
ing by trained nurses and processed for biochemi-
cal determinations. The concentration of capillary 
blood glucose was determined by an Accu-Chek® 
Aviva (Roche Diagnostics, Mannheim, Germany). 
HbA1c was assayed on K2-ethylenediaminetet-
raacetic acid (EDTA) blood specimens (Becton 
Dickinson, Nairobi, Kenya), using a DCA-2000+® an-
alyzer (Siemens, Marburg, Germany). Fructosa-
mine (1-amino-1-deoxy-D-fructose) was measured 
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in serum samples (Becton Dickinson, Nairobi, Ken-
ya) and in nail fragments using a nitro blue tetra-
zolium (NBT) colorimetric method and a commer-
cial fructosamine standard (Roche Diagnostics, 
Mannheim, Germany) (6). 
Distal human finger nail fragments were collected 
using a classic nail clipper. The size of the nail frag-
ments ranged from 0.3 to 3.0 mg per fragment. As 
previously demonstrated (4), treatment with de-
tergent (soap) had no influence on the measured 
concentration of glycated nail proteins. After 
weighing, the nail clippings were transferred into a 
standard 10 mm pathway cuvette. One mL of fruc-
tosamine reagent (0.25 mmol/L NBT (Sigma, St. 
Louis, MO, USA) in a 0.1 mol/L sodium carbonate/
bicarbonate buffer (pH: 10.3), containing 0.1% Tri-
ton X-100 (Fluka, St. Louis, MO, USA)), was added to 
the nail clippings. Following incubation (37 °C, 60 
min), photometric readings occurred at 530 nm in 
a UV-1800 photometer (Shimadzu, Kyoto, Japan). 
The spontaneous rate of hydrolysis of the NBT dye 
is very low and below the detection limit within 
the observation period (60 min). A commercial 
fructosamine standard (Roche, Mannheim, Germa-
ny) was used for standardizing the assay. For inter-
nal quality control, commercial fructosamine 
standards (Roche Diagnostics, Mannheim, Germa-
ny) have been assigned. Results were expressed as 
µmol of fructosamine per g of nail. The within-run 
CV of the assay was 11%. 
The blood analyses and the measurement of gly-
cated nail fragments were performed once in all 
subjects at the start of the study. However in a 
subgroup of 30 diabetic patients, this procedure 
was repeated after 6 months of antidiabetic treat-
ment. 
Statistical analysis
All values are expressed as mean ± standard devia-
tion (SD) (when data were normally distributed) or 
median ± IQR (when data were not normally dis-
tributed). Receiver operating characteristics curve 
(ROC) analysis was used for calculation of cut-off 
values. The normality of the data distribution was 
evaluated by the Kolmogorov-Smirnov test. For 
comparison of continuous variables, non-para-
metric Mann-Whitney U test was used. For the 
analysis of the paired data in the subgroup of 30 
diabetics, paired Student’s t-test was used, as the 
data were normally distributed. A P-value < 0.05 
was considered to be statistically significant. Sta-
tistical analyses were performed using MedCalc® 
(MedCalc Version 15.5, Mariakerke, Belgium).
Results
ROC analysis yielded an AUC of 0.71 [95% confi-
dence interval (CI): 0.65-0.76] and a cut-off point of 
3.83 μmol/g nail (corresponding with a specificity 
of 68.3% and a sensitivity of 67.2%). At the start of 
the study period, the concentrations of fasting 
blood glucose, serum fructosamine, HbA1c and 
glycated nail proteins were significantly higher (P 
< 0.001) in the group of diabetic patients in com-
parison with the non-diabetics (Table 1). 
In a subgroup of 30 diabetic patients, the course of 
the concentration of two short-term (fasting glu-
cose concentration and serum fructosamine con-
centration) and two long-term (glycated nail pro-
tein concentration and HbA1c value) glycemic bio-
markers was documented at start of the study and 
after 6 months of antidiabetic treatment (Table 2). 
Biochemical parameter Diabetes(N = 163)
Non-diabetics
(N = 67) P-value
Fasting blood glucose (mmol/L) 9.7 (7.5-14.8) 4.7 (3.7-5.2) < 0.001
Serum fructosamine (µmol/L) 422 (333-540) 280 (237-350) < 0.001
Hemoglobin A1c (mmol/mol) 73 (59-98) 33 (31-36) < 0.001
Glycated nail protein (µmol/g nail) 5.30 (2.80-9.12) 2.90 (1.42-4.97) < 0.001
Table 1. Comparison of biochemical parameters between patients with diabetes mellitus and non-diabetics.
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A significant drop in the fasting blood glucose 
concentration (P = 0.017) and glycated nail protein 
concentration (P = 0.008) was observed in contrast 
to the non-significant changes in the serum fruc-
tosamine concentration and the HbA1c level. 
Discussion
In an African district hospital, we have demon-
strated for the first time the value of measuring 
the concentration of glycated nail proteins for the 
diagnosis of diabetes mellitus in a South Kivu Con-
golese population group. Although HbA1c has 
been incorporated into the new guidelines to di-
agnose diabetes mellitus (7), the use of this bio-
marker in Africa is not only hampered by infra-
structural and financial problems. The presence of 
haemoglobinopathies (e.g. thalassaemias and 
sickle cell anemia) could influence the interpreta-
tion of the measured HbA1c levels and population-
specific optimum cut-off points might be neces-
sary for different ethnic groups and populations 
(8-11). In addition, the use of the proposed alterna-
tive glycemic biomarker could be very useful in 
developing countries as it has a less critical prean-
alytical phase and can be performed with low rea-
gent costs.
In addition, the present study shows that the 
measurement of glycated nail proteins could be 
used to monitor diabetes mellitus over a long time 
period in black subjects of sub-Saharan Africa. Fin-
ger nails grow slowly at approximately 2-3 mm/
month with a complete replacement performed 
between 6 and 9 months. This period allows a 
long exposure of the nail to the glycemic environ-
ment. As demonstrated in previous experiments 
(12), glycation of nail proteins takes place in the 
deep layer of finger nails. Using a hand piece con-
taining a latch-type-bur, a meticulous cutting of 
the nail plate into superficial and deep layers was 
performed. Measuring the concentration of fruc-
tosamine in the superficial and deep nail layers, 
significantly lower glycated nail protein concentra-
tions were found in the superficial nail layer in 
comparison with the deep layer. In contrast to the 
superficial nail layer, the deep layer is in close con-
tact with the blood vessels and the interstitial flu-
id. 
Discordances between HbA1c and other glycemic 
biomarkers have already been reported (13). The 
lack of a significant correlation between the con-
centration of glycated nail proteins and the serum 
fructosamine concentration and the HbA1c values 
could be explained by several reasons: a different 
exposure time to extracellular glucose (> 6 months 
for glycated nail proteins versus 10-14 days for se-
rum fructosamine and 120 days for HbA1c), the 
unique valine linked glycation of HbA1c and the 
variable glucose diffusion rate from the vascular 
system to the nail bed (12). As demonstrated previ-
ously (6), the positive correlation between the con-
centrations of glycated nail and eye lens proteins 
suggests that the presented biomarker has also 
the potential to predict diabetic glycation-associ-
ated target organ damage. 
A first limitation of this study was the monocentric 
character. A second limitation was that the fasting 
blood glucose concentration was determined on 
capillary blood and that we did not perform an 
oral glucose tolerance test to diagnose diabetes 
Biochemical parameter Diabetics, month 0(N = 30)
Diabetics, month 6
(N = 30) P-value
Fasting blood glucose (mmol/L) 8.2 ± 4.2 7.2 ± 2.0 0.017
Serum fructosamine (µmol/L) 443 ± 113 367 ± 218 0.113
Hemoglobin A1c (mmol/mol) 71 ± 21 67 ± 23 0.306
Glycated nail protein (µmol/g nail) 6.5 ± 4.9 3.8 ± 2.5 0.008
Table 2. Comparison of biochemical parameters between patients with diabetes mellitus initially (month = 0) and after 6 months of 
antidiabetic treatment.
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mellitus. Finally, the course of the different short-
term (fasting glucose concentration and serum 
fructosamine concentration) and long-term (gly-
cated nail protein concentration, HbA1c level) gly-
cemic biomarkers was only followed in a small 
subgroup of diabetics. Large-scale prospective 
clinical trials are necessary to confirm our results.
To conclude, measurement of glycated nail pro-
teins could be used to diagnose and to monitor 
diabetes mellitus in black subjects of sub-Saharan 
Africa. 
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